利托那韦-话题@MedSci

#利托那韦#

38篇内容 | 1550人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1560150, encodeId=d5c01560150ff, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=Front Pharmacol：基于洛匹那韦/利托那韦的**和替代二线方案在HIV感染患者中的疗效, objectType=article, longId=164255, objectId=4e0616425517, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e0616425517, replyNumber=0, likeNumber=73, createdTime=2019-04-15, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e0616425517, moduleTitle=Front Pharmacol：基于洛匹那韦/利托那韦的**和替代二线方案在HIV感染患者中的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e0616425517)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1566159, encodeId=2f27156615923, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=Front Pharmacol：基于洛匹那韦/利托那韦的**和替代二线方案在HIV感染患者中的疗效, objectType=article, longId=164255, objectId=4e0616425517, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e0616425517, replyNumber=0, likeNumber=46, createdTime=2019-04-15, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e0616425517, moduleTitle=Front Pharmacol：基于洛匹那韦/利托那韦的**和替代二线方案在HIV感染患者中的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e0616425517)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1560149, encodeId=9b1515601495e, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=2000 - 2014年西班牙马德里感染艾滋病毒1型儿童和青少年的洛匹那韦-利托那韦治疗的效果, objectType=article, longId=164135, objectId=2a1b164135f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a1b164135f0, replyNumber=0, likeNumber=65, createdTime=2019-04-14, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a1b164135f0, moduleTitle=2000 - 2014年西班牙马德里感染艾滋病毒1型儿童和青少年的洛匹那韦-利托那韦治疗的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a1b164135f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1566158, encodeId=ee9815661580c, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=2000 - 2014年西班牙马德里感染艾滋病毒1型儿童和青少年的洛匹那韦-利托那韦治疗的效果, objectType=article, longId=164135, objectId=2a1b164135f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a1b164135f0, replyNumber=0, likeNumber=61, createdTime=2019-04-14, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a1b164135f0, moduleTitle=2000 - 2014年西班牙马德里感染艾滋病毒1型儿童和青少年的洛匹那韦-利托那韦治疗的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a1b164135f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1560148, encodeId=78551560148ce, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=真实世界研究显示，基于度鲁特韦和利托那韦增强的达芦那韦（DTG/DRV/r）的双重疗法是HIV-1患者安全且有效的疗法, objectType=article, longId=163954, objectId=7a891639548d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a891639548d, replyNumber=0, likeNumber=111, createdTime=2019-04-11, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a891639548d, moduleTitle=真实世界研究显示，基于度鲁特韦和利托那韦增强的达芦那韦（DTG/DRV/r）的双重疗法是HIV-1患者安全且有效的疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a891639548d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1566157, encodeId=da6f156615e4b, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=真实世界研究显示，基于度鲁特韦和利托那韦增强的达芦那韦（DTG/DRV/r）的双重疗法是HIV-1患者安全且有效的疗法, objectType=article, longId=163954, objectId=7a891639548d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a891639548d, replyNumber=0, likeNumber=99, createdTime=2019-04-11, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a891639548d, moduleTitle=真实世界研究显示，基于度鲁特韦和利托那韦增强的达芦那韦（DTG/DRV/r）的双重疗法是HIV-1患者安全且有效的疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a891639548d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1560147, encodeId=dab8156014e1e, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=Antimicrob Agents Ch：HIV儿童：洛匹那韦-利托那韦与MDR-TB常用药联用时相互作用如何？, objectType=article, longId=131246, objectId=42ed13124630, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42ed13124630, replyNumber=0, likeNumber=94, createdTime=2018-03-04, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42ed13124630, moduleTitle=Antimicrob Agents Ch：HIV儿童：洛匹那韦-利托那韦与MDR-TB常用药联用时相互作用如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=42ed13124630)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1566156, encodeId=c8b8156615631, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=Antimicrob Agents Ch：HIV儿童：洛匹那韦-利托那韦与MDR-TB常用药联用时相互作用如何？, objectType=article, longId=131246, objectId=42ed13124630, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42ed13124630, replyNumber=0, likeNumber=49, createdTime=2018-03-04, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42ed13124630, moduleTitle=Antimicrob Agents Ch：HIV儿童：洛匹那韦-利托那韦与MDR-TB常用药联用时相互作用如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=42ed13124630)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1566155, encodeId=91d8156615519, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=EUR J Cancer：来源于ModraDoc001或ModraDoc006的多西紫杉醇联合利托那韦的剂量扩大研究, objectType=article, longId=124483, objectId=4a021244830a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a021244830a, replyNumber=0, likeNumber=70, createdTime=2017-12-26, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a021244830a, moduleTitle=EUR J Cancer：来源于ModraDoc001或ModraDoc006的多西紫杉醇联合利托那韦的剂量扩大研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a021244830a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1560146, encodeId=c1ba15601467a, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=EUR J Cancer：来源于ModraDoc001或ModraDoc006的多西紫杉醇联合利托那韦的剂量扩大研究, objectType=article, longId=124483, objectId=4a021244830a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a021244830a, replyNumber=0, likeNumber=71, createdTime=2017-12-26, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a021244830a, moduleTitle=EUR J Cancer：来源于ModraDoc001或ModraDoc006的多西紫杉醇联合利托那韦的剂量扩大研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a021244830a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1566154, encodeId=e1a51566154b7, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=艾伯维修订增强型拟肽类PIs口服联合制剂克力芝®（洛匹那韦/利托那韦）的说明书, objectType=article, longId=121164, objectId=247f1211642b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=247f1211642b, replyNumber=0, likeNumber=73, createdTime=2017-11-25, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=247f1211642b, moduleTitle=艾伯维修订增强型拟肽类PIs口服联合制剂克力芝®（洛匹那韦/利托那韦）的说明书, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=247f1211642b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1560145, encodeId=18bf15601453f, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=艾伯维修订增强型拟肽类PIs口服联合制剂克力芝®（洛匹那韦/利托那韦）的说明书, objectType=article, longId=121164, objectId=247f1211642b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=247f1211642b, replyNumber=0, likeNumber=73, createdTime=2017-11-25, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=247f1211642b, moduleTitle=艾伯维修订增强型拟肽类PIs口服联合制剂克力芝®（洛匹那韦/利托那韦）的说明书, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=247f1211642b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1566153, encodeId=84201566153fc, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=Lancet：洛匹那韦–利托那韦加上拉米夫定对HIV-1病毒抑制的维持, objectType=article, longId=51817, objectId=9fec5181e83, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fec5181e83, replyNumber=0, likeNumber=91, createdTime=2015-06-10, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fec5181e83, moduleTitle=Lancet：洛匹那韦–利托那韦加上拉米夫定对HIV-1病毒抑制的维持, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fec5181e83)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1560144, encodeId=ef3d15601443c, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=Lancet：洛匹那韦–利托那韦加上拉米夫定对HIV-1病毒抑制的维持, objectType=article, longId=51817, objectId=9fec5181e83, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fec5181e83, replyNumber=0, likeNumber=73, createdTime=2015-06-10, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fec5181e83, moduleTitle=Lancet：洛匹那韦–利托那韦加上拉米夫定对HIV-1病毒抑制的维持, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fec5181e83)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1560143, encodeId=1a631560143c5, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=CPP：利托那韦显著改变多西他赛暴露水平, objectType=article, longId=34272, objectId=f0a6342e2b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0a6342e2b0, replyNumber=0, likeNumber=91, createdTime=2014-05-07, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0a6342e2b0, moduleTitle=CPP：利托那韦显著改变多西他赛暴露水平, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0a6342e2b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1566152, encodeId=efca15661527a, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=CPP：利托那韦显著改变多西他赛暴露水平, objectType=article, longId=34272, objectId=f0a6342e2b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0a6342e2b0, replyNumber=0, likeNumber=95, createdTime=2014-05-07, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0a6342e2b0, moduleTitle=CPP：利托那韦显著改变多西他赛暴露水平, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0a6342e2b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1566151, encodeId=ba3c156615105, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=CID：洛匹那韦/利托那韦单一疗法可有效预防HIV-1的母婴传播, objectType=article, longId=20251, objectId=901b20251b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=901b20251b9, replyNumber=0, likeNumber=110, createdTime=2013-06-20, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=901b20251b9, moduleTitle=CID：洛匹那韦/利托那韦单一疗法可有效预防HIV-1的母婴传播, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=901b20251b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1560142, encodeId=d38e1560142ef, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=CID：洛匹那韦/利托那韦单一疗法可有效预防HIV-1的母婴传播, objectType=article, longId=20251, objectId=901b20251b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=901b20251b9, replyNumber=0, likeNumber=104, createdTime=2013-06-20, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=901b20251b9, moduleTitle=CID：洛匹那韦/利托那韦单一疗法可有效预防HIV-1的母婴传播, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=901b20251b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

利托那韦

2020-05-29

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

Front Pharmacol：基于洛匹那韦/利托那韦的**和替代二线方案在HIV感染患者中的疗效

2019-04-15

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

Front Pharmacol：基于洛匹那韦/利托那韦的**和替代二线方案在HIV感染患者中的疗效

2019-04-15

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

2000 - 2014年西班牙马德里感染艾滋病毒1型儿童和青少年的洛匹那韦-利托那韦治疗的效果

2019-04-14

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

2000 - 2014年西班牙马德里感染艾滋病毒1型儿童和青少年的洛匹那韦-利托那韦治疗的效果

2019-04-14

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

真实世界研究显示，基于度鲁特韦和利托那韦增强的达芦那韦（DTG/DRV/r）的双重疗法是HIV-1患者安全且有效的疗法

2019-04-11

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

真实世界研究显示，基于度鲁特韦和利托那韦增强的达芦那韦（DTG/DRV/r）的双重疗法是HIV-1患者安全且有效的疗法

2019-04-11

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

Antimicrob Agents Ch：HIV儿童：洛匹那韦-利托那韦与MDR-TB常用药联用时相互作用如何？

2018-03-04

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

Antimicrob Agents Ch：HIV儿童：洛匹那韦-利托那韦与MDR-TB常用药联用时相互作用如何？

2018-03-04

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

EUR J Cancer：来源于ModraDoc001或ModraDoc006的多西紫杉醇联合利托那韦的剂量扩大研究

2017-12-26

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

EUR J Cancer：来源于ModraDoc001或ModraDoc006的多西紫杉醇联合利托那韦的剂量扩大研究

2017-12-26

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

艾伯维修订增强型拟肽类PIs口服联合制剂克力芝®（洛匹那韦/利托那韦）的说明书

2017-11-25

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

艾伯维修订增强型拟肽类PIs口服联合制剂克力芝®（洛匹那韦/利托那韦）的说明书

2017-11-25

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

Lancet：洛匹那韦–利托那韦加上拉米夫定对HIV-1病毒抑制的维持

2015-06-10

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

Lancet：洛匹那韦–利托那韦加上拉米夫定对HIV-1病毒抑制的维持

2015-06-10

zhouqu_8 (审核中...)

前往app查看评论内容

#利托那韦#

CPP：利托那韦显著改变多西他赛暴露水平

2014-05-07

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

CPP：利托那韦显著改变多西他赛暴露水平

2014-05-07

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

CID：洛匹那韦/利托那韦单一疗法可有效预防HIV-1的母婴传播

2013-06-20

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

CID：洛匹那韦/利托那韦单一疗法可有效预防HIV-1的母婴传播

2013-06-20

科室
- - 订阅+
  - 更多科室
工具
服务